NF-κB Pathway and Its Inhibitors: A Promising Frontier in the Management of Alzheimer's Disease

Biomedicines. 2023 Sep 21;11(9):2587. doi: 10.3390/biomedicines11092587.

Abstract

The nuclear factor kappa B (NF-κB) pathway has emerged as a pivotal player in the pathogenesis of various diseases, including neurodegenerative illnesses like Alzheimer's disease (AD). The involvement of the NF-κB pathway in immune system responses, inflammation, oxidative stress, and neuronal survival highlights its significance in AD progression. We discuss the advantages of NF-κB pathway inhibition, including the potential to mitigate neuroinflammation, modulate amyloid beta (Aβ) production, and promote neuronal survival. However, we also acknowledge the limitations and challenges associated with this approach. Balancing the fine line between dampening inflammation and preserving physiological immune responses is critical to avoid unintended consequences. This review combines current knowledge on the NF-κB pathway's intricate involvement in AD pathogenesis, emphasizing its potential as a therapeutic target. By evaluating both advantages and limitations, we provide a holistic view of the feasibility and challenges of NF-κB pathway modulation in AD treatment. As the quest for effective AD therapies continues, an in-depth understanding of the NF-κB pathway's multifaceted roles will guide the development of targeted interventions with the potential to improve AD management.

Keywords: Alzheimer’s disease; NF-κB; amyloid beta plaques; neuroinflammation; phytochemicals.

Publication types

  • Review

Grants and funding

This research was funded by Fundamental Fund Research, Chiang Mai University, Chiang Mai, Thailand.